Description:
Remogliflozin etabonat, pro-drug of remogliflozin, is a SGLT2 inhibitor under development for the treatment of type 2 diabetes. Remogliflozin etabonate is a pro-drug of remogliflozin, inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney.
- Molecular Weight: 522.59
- Molecular Formula: C26H38N2O9
Purity: ≥98%
Canonical SMILES:
CC1=CC2=C(C=C1)N(C3C2CN(CC3)C)C(=O)CSC4=NN=NN4C5=CC=C(C=C5)Cl
InChI:
1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
InChIKey: UAOCLDQAQNNEAX-ABMICEGHSA-N
- Solubility: Soluble in DMSO
- Appearance: Solid powder
- Application: SGLT2 inhibitor
- Storage: Store at -20 °C
Synonyms:
GSK189075A; GSK-189075A; GSK 189075A; GSK189075; GSK-189075; GSK 189075; Remogliflozin etabonate.beta-D-Glucopyranoside, 5-methyl-4-((4-(1-methylethoxy)phenyl)methyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 6-(ethyl carbonate);
More details are to be found on supplier website
